A detailed history of Gsa Capital Partners LLP transactions in Myriad Genetics Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 18,420 shares of MYGN stock, worth $248,670. This represents 0.04% of its overall portfolio holdings.

Number of Shares
18,420
Holding current value
$248,670
% of portfolio
0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$23.97 - $28.6 $441,527 - $526,812
18,420 New
18,420 $505,000
Q2 2020

Aug 11, 2020

SELL
$10.69 - $16.49 $203,077 - $313,260
-18,997 Closed
0 $0
Q1 2020

May 12, 2020

BUY
$9.78 - $29.53 $61,584 - $185,950
6,297 Added 49.58%
18,997 $272,000
Q4 2019

Feb 12, 2020

BUY
$20.93 - $35.1 $66,976 - $112,320
3,200 Added 33.68%
12,700 $346,000
Q3 2019

Nov 12, 2019

BUY
$22.08 - $47.08 $209,759 - $447,260
9,500 New
9,500 $272,000
Q2 2019

Aug 06, 2019

SELL
$22.67 - $35.0 $1.41 Million - $2.18 Million
-62,224 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$26.93 - $34.7 $296,203 - $381,665
10,999 Added 21.47%
62,224 $2.07 Million
Q4 2018

Feb 12, 2019

BUY
$27.23 - $45.56 $749,505 - $1.25 Million
27,525 Added 116.14%
51,225 $1.49 Million
Q3 2018

Nov 13, 2018

SELL
$37.57 - $50.34 $1.39 Million - $1.87 Million
-37,100 Reduced 61.02%
23,700 $1.09 Million
Q2 2018

Aug 09, 2018

SELL
$27.75 - $40.17 $555,000 - $803,400
-20,000 Reduced 24.75%
60,800 $2.27 Million
Q1 2018

May 11, 2018

SELL
$28.83 - $41.01 $526,378 - $748,760
-18,258 Reduced 18.43%
80,800 $2.39 Million
Q4 2017

Feb 14, 2018

BUY
$28.45 - $37.14 $741,350 - $967,794
26,058 Added 35.7%
99,058 $3.4 Million
Q3 2017

Nov 20, 2017

BUY
$24.01 - $36.2 $1.75 Million - $2.64 Million
73,000
73,000 $2.64 Million

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.09B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.